Receptor News and Research

RSS

Oral GLP-1 RA reduces blood glucose and bodyweight among people with type 2 diabetes

Oral GLP-1 medications have the potential to increase access to therapies that can help lower blood sugar and reduce bodyweight.

8 Jun 2026

GLP-1 users say the drugs quiet food noise but do not replace lifestyle change

A qualitative study of 30 US adults found that GLP-1 receptor agonists often reduced “food noise,” psychological hunger, and appetite, helping patients feel more able to make deliberate lifestyle changes.

8 Jun 2026

Expert review examines widely-held beliefs about dietary protein needs and benefits

A newly published peer-reviewed paper in Critical Reviews in Food Science and Nutrition synthesizes findings from a February 2025 scientific workshop.

8 Jun 2026

Weight loss drugs linked to lower risk of alcohol, opioid, nicotine and cocaine use disorders

A new study led by researchers at The University of Texas at El Paso found that use of weight loss drugs like Ozempic and other GLP-1s is associated with a lower risk of developing alcohol, opioid, nicotine and cocaine use disorders.

8 Jun 2026

Weight loss medications show promise in preventing obesity-related cancers

A study of more than 229,000 obese adults without diabetes in the United States has shown that weight loss drugs are associated with a decreased risk of obesity-related cancers.

7 Jun 2026

GLP-1 therapies linked to fewer complications in adults with both obesity and autoimmune disease

Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) medication had lower rates of emergency department visits and were less likely to experience serious cardiac events, such as stroke, pulmonary embolism or death when compared to similar adults who were not taking these medications, according to new research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.

7 Jun 2026

Microbially modified bile acids influence sleep apnea outcomes

Studies in mice reveal a new target for potentially treating and preventing life-threatening cardiovascular complications in the millions of patients with sleep apnea worldwide.

7 Jun 2026

Major trials show finerenone preserves kidney function beyond diabetes

A series of major studies has shown that finerenone preserves kidney function, reduces cardiovascular risk, and improves survival across a much broader range of patients with chronic kidney disease (CKD) than it is currently recommended for.

5 Jun 2026

Finerenone slows kidney function decline in non-diabetic patients

The drug finerenone significantly slows the decline in kidney function in patients with chronic kidney disease (CKD) who do not have diabetes.

4 Jun 2026

Repurposed cancer therapy enables successful kidney transplantation

A pioneering clinical trial has successfully enabled three patients with end-stage kidney disease to receive previously improbable kidney transplants.

4 Jun 2026

Why exercise matters for obesity even when the scale barely moves

AHA's scientific statement reveals exercise's vital role in obesity management, boosting cardiovascular health and supporting long-term weight loss efforts.

4 Jun 2026

Real-world study exposes suboptimal adherence to treat-to-target rheumatic strategies

EULAR - The European Alliance of Associations for Rheumatology - acknowledges the role of diverse real-world data to complement knowledge from randomized controlled trials.

4 Jun 2026

Histamine boost helps the brain remember, decide, and learn from loss

Pitolisant, a histamine H3 receptor inverse agonist, improved recognition memory, working memory performance, and reinforcement learning in healthy adults. The findings suggest that histamine helps shape how the brain stabilizes new memories, accumulates evidence for decisions, and avoids overreacting to negative outcomes.

3 Jun 2026

Semaglutide boosts well-being among patients with diabetes and CKD

New findings from the landmark FLOW trial, presented at the 63rd ERA Congress, show that once-weekly semaglutide significantly improved health-related quality of life in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD), equivalent to around eight additional days in full health per year.

3 Jun 2026

Novel CAR T treatment makes previously impossible kidney transplants possible

A pioneering clinical trial has successfully enabled two patients with end-stage kidney disease to receive previously improbable kidney transplants.

3 Jun 2026

Could GLP-1 drugs help prevent breast cancer? New study points to a possible link

A large retrospective cohort study of 111,646 overweight or obese women found that GLP-1 agonist exposure was associated with lower breast cancer incidence. After propensity-score matching, GLP-1 exposure was linked to nearly 30% lower odds of breast cancer, but the authors stress that randomized trials are needed before these drugs can be considered for prevention.

3 Jun 2026

CAR-T cell therapy shows promise for treating rheumatoid arthritis

Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare.

3 Jun 2026

GLP-1 treatments may reduce knee replacement surgery rates

GLP-1 receptor agonist drugs, used for the treatment of diabetes, and more recently, weight loss, are associated with a significantly lower long term risk of knee replacement surgery as a result of osteoarthritis, finds an analysis of medical records data, published in the open access journal Regional Anesthesia & Pain Medicine.

2 Jun 2026

GLP-1 therapy linked to slower biological aging processes

Glucagon-like peptide-1 (GLP-1) receptor agonist medications have gained widespread attention for effectively treating obesity, lowering blood sugar and decreasing the risk of cardiovascular disease.

2 Jun 2026

Three-drug strategy forces pancreatic tumors into lasting regression

A triple-targeted preclinical therapy combining daraxonrasib, afatinib, and SD36 drove durable pancreatic cancer regression by blocking KRAS/RAS, EGFR/HER2, and STAT3 signaling. The approach prevented treatment resistance across mouse and human tumor-derived models, but remains preclinical and requires more clinically suitable drug combinations before human testing.

2 Jun 2026